{"prompt": "['Novartis', 'Confidential', 'Page 52', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '6.5.2 Vital signs', 'Systolic and diastolic blood pressure and radial pulse rate (over a 30 sec interval), performed', 'in the sitting position, will be recorded at scheduled visits as detailed in Schedule of', 'Assessments Table 6-1. Vitals can be performed just before or just after ECG.', '6.5.3 Height and weight', 'Height in centimeters (cm) will be measured. Body weight (to the nearest 0.1 kilogram [kg] in', 'indoor clothing, but without shoes) will be measured according to Schedule of Assessments', 'Table 6-1. BMI will be calculated based on height and weight.', '6.5.4 Laboratory evaluations', 'A central laboratory will be used for analysis of all specimens collected. Details on the', 'collections, shipment of samples and reporting of results by the central laboratory are', 'provided to investigators in the laboratory manual.', 'All patients with laboratory tests containing clinically significant abnormalities should be', 'followed regularly until the values return to within the normal ranges or until a valid reason', 'other than drug-related adverse experiences is identified, even after the medication has', 'discontinued.', 'Safety Laboratory assessments (hematology, clinical chemistry, urinalysis) will be performed', 'according to Schedule of Assessments Table 6-1.', '6.5.4.1 Hematology', 'Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, and', 'platelet count will be measured.', '6.5.4.2 Clinical chemistry', 'Albumin, alkaline phosphatase, AST (SGOT), ALT (SGPT), bilirubin, creatinine, Y-GT,', 'glucose, potassium, magnesium, BUN and uric acid will be measured.', 'If the total bilirubin concentration is increased above 1.5 times the upper limit of normal', 'range, total bilirubin should be differentiated into the direct and indirect reacting bilirubin.', '6.5.4.3 Urinalysis', 'Dipstick measurements for specific gravity, pH, protein, glucose and blood will be performed', 'according to the Schedule of Assessments Table 6-1.', 'If the urine dipstick is abnormal, the sample will be sent to central laboratory for additional', 'testing, including assessment of WBC and RBC sediments.', '6.5.5 Electrocardiogram (ECG)', 'ECGs must be recorded after 10 minutes rest in the supine position to ensure a stable baseline.', 'Centralized ECG equipment:']['Novartis', 'Confidential', 'Page 53', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'ECGs will be measured pre-dose. All electrocardiograms should include 12 standard leads.', 'An ECG tracing will be taken for those patients who prematurely discontinue from the study.', 'Each ECG will be sent electronically from the ECG machine to the central laboratory. A print', 'out of the ECG record will be generated and kept at the investigator site as source', 'documentation and as back-up for submission to the central laboratory in case of problems', 'with the electronic transmission. Each print out will be kept at the investigator site and will be', \"dated and signed. The subject's number, the date, actual time of the tracing, and Study Code\", 'must appear on each page of the tracing.', 'Full details of all procedures relating to the ECG collection and reporting will be contained in', 'an investigator manual to be provided by the central laboratory to each investigator site. A', 'clinically significant abnormality should be reported as an AE. If necessary a cardiologist may', 'be consulted.', 'Clinically significant ECG findings at baseline must be discussed with the sponsor before', 'administration with investigational treatment.', 'If a patient experiences a clinically significant change in cardiac rhythm or other clinically', 'significant cardiovascular abnormality, the investigator should consider withdrawing the', 'patient from the study.', 'Clinically significant abnormalities should be recorded on the relevant section of the medical', 'history/Current medical conditions/AE CRF/e-CRF page as appropriate.', 'New cases (not present during screening/run-in periods) of atrial fibrillation reported from the', 'ECG measurements (or reported as an AE during the course of the study) will be adjudicated.', 'Additional information regarding the Atrial Fibrillation/Atrial Flutter may be requested to be', 'sent to the Adjudication Committee. All cases of atrial fibrillation, regardless of seriousness,', 'will be reviewed by the Adjudication Committee.', '6.5.6 Pregnancy and assessments of fertility', 'A urine or serum pregnancy test will be performed in pre-menopausal women who are not', 'surgically sterile (tests provided by the Central Laboratory) per Schedule of Assessments', 'Table 6-1. If the urine pregnancy test is positive, a plasma testing is to be done to confirm the', 'pregnancy. A positive pregnancy test during the study requires the patient to be discontinued', 'from the study treatment. Refer to Section 5.6.2 and Section 7.5 for more details. Additional', 'pregnancy testing might be performed if requested by local requirements.', '6.5.7 Appropriateness of safety measurements', 'The safety assessments selected are standard for this indication/patient population.']\n\n###\n\n", "completion": "END"}